Drug Trial Radar · NCT07011511
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Dec 2, 2027
Study completion Dec 2, 2027
Sponsor
- Lead sponsor
- Medicines for Malaria VentureAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Quotient Sciences; The Doctors Laboratory Ltd
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of MMV055 administered alone (Part A) and in combination with MMV371 (Part B) in healthy participants. It is planned to enroll up to 6 sequential cohorts of 8 healthy male participants and healthy female participants of non-childbearing potential in Part A. In Part B, up to 3 sequential cohorts of 8 healthy male participants and healthy non-pregnant, non-lactating female participants will be enrolled. In each cohort, participants will be randomised in a ratio of 6 active investigational medicinal product (IMP) to 2 placebo. Part A of the study will include two components, Parts A1 and A2. Part A1 includes two initial cohorts, with planned doses of 40 and 100mg, respectively. It is intended to document the human elimination T1/2 of MMV055, which will then be used to shorten the proposed End of Study (EOS) of 48 weeks, if possible. All cohorts will follow a sentinel dosing design. On Day 1, two sentinel participants (sentinel group) will be randomly assigned to receive a single IM dose of either active IMP or placebo (1 participant each) to assess safety and tolerability (including ISRs). The sentinel group will be dosed concomitantly at least 7 days prior to the rest of the cohort (main group). The main group will comprise 6 participants randomly assigned to receive a single IM dose of either active IMP or placebo in a 5:1 ratio to assess safety and tolerability (including ISRs).
Conditions
- Malaria, Falciparum
Interventions
MMV055 Dose 1Drug
40mg
MMV055 Dose 2Drug
100mg
MMV055 Dose 3Drug
200mg
MMV055 Dose 4Drug
400mg
MMV055 Dose 5Drug
800mg
MMV055 Dose 6Drug
TBCmg
Matching placebo Part ADrug
Part A
Matching placebo Part BDrug
Part B
MMV055/MMV371 Combo 1Combination product
Combination 1
MMV055/MM371 Combo 2Combination product
Combination 2
MMV055/MMV371 Combo 3Combination product
Combination 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Incidence of AEsTime frame: From enrollment to the last follow up visit at week 56
- Safety - Incidence of Injection Site ReactionsTime frame: From enrollment to the last follow up visit at week 56
- Safety - Incidence of physical examination findingsTime frame: From enrollment to the last follow up visit at week 56
- Safety - Vital signs changes from baselineTime frame: From enrollment to the last follow up visit at week 56
- Safety - ECG changes from baseline, QT intervalsTime frame: From enrollment to the last follow up visit at week 56
- Safety - ECG changes from baseline, PR and QRS intervalsTime frame: From enrollment to the last follow up visit at week 56
- Part 1 only: plasma concentrations of MMV055: CmaxTime frame: From enrollment to the last follow up visit at week 56
- Part 1 only: plasma concentrations of MMV055: AUC(0-last)Time frame: From enrollment to the last follow up visit at week 56
- Part 1 only: plasma concentrations of MMV055: AUC(0-inf)Time frame: From enrollment to the last follow up visit at week 56
- Part 1 only: plasma concentrations of MMV055: T1/2Time frame: From enrollment to the last follow up visit at week 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.